Trials / Completed
CompletedNCT00905086
Psychosocial Adjustment After Radiation Therapy in Patients With Cancer
Psychosocial Adjustment During the Post-Radiation Treatment Transition
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 80 (actual)
- Sponsor
- Case Comprehensive Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
RATIONALE: Gathering information about psychological and social adjustment after radiation therapy in patients with cancer may help doctors plan the best treatment. PURPOSE: This clinical trial is studying psychosocial adjustment after radiation therapy in patients with breast cancer, colorectal cancer, lung cancer, or prostate cancer.
Detailed description
OBJECTIVES: * To describe psychosocial adjustment after radiotherapy in patients with stage I, II, or III breast, colorectal, lung, or prostate cancer. * To determine if cognitive appraisal of health predicts psychosocial adjustment of these patients after radiotherapy. * To examine whether social support moderates the relationship between cognitive appraisal of health and psychosocial adjustment of these patients after radiotherapy. * To examine whether self-efficacy for coping with cancer moderates the relationship between cognitive appraisal of health and psychosocial adjustment of these patients after radiotherapy. * To measure the effect of symptom distress, uncertainty, medical factors, and personal factors on cognitive appraisal of health of these patients before ending radiotherapy. OUTLINE: Two weeks before completing planned radiotherapy, patients undergo assessment of stress appraisal and other factors predictive of post-radiotherapy psychosocial adjustment. Patients complete psychosocial assessments, including measures of patient perceptions of their illness (i.e., cognitive appraisal) and of the factors influencing their perceptions (i.e., uncertainty by the Mishel Uncertainty in Illness Scale-Community Form; symptom distress by the Memorial Symptom Assessment Scale Short Form; and comorbidity by the Charlson Comorbidity Index). Measures of patient social support and self-efficacy for coping are also assessed. At 1 month after completion of radiotherapy, patients undergo repeat assessment of stress appraisal and psychosocial adjustment.
Conditions
- Breast Cancer
- Cognitive/Functional Effects
- Colorectal Cancer
- Lung Cancer
- Prostate Cancer
- Psychosocial Effects of Cancer and Its Treatment
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | questionnaire administration | Two weeks before completing planned radiotherapy, patients undergo assessment of stress appraisal and other factors predictive of post-radiotherapy psychosocial adjustment. At 1 month after completion of radiotherapy, patients undergo repeat assessment of stress appraisal and psychosocial adjustment. |
| PROCEDURE | cognitive assessment | Patients complete psychosocial assessments, including measures of patient perceptions of their illness (i.e., cognitive appraisal) and of the factors influencing their perceptions (i.e., uncertainty by the Mishel Uncertainty in Illness Scale-Community Form; symptom distress by the Memorial Symptom Assessment Scale Short Form; and comorbidity by the Charlson Comorbidity Index). |
| PROCEDURE | psychosocial assessment and care | Patients complete psychosocial assessments, including measures of patient perceptions of their illness (i.e., cognitive appraisal) and of the factors influencing their perceptions (i.e., uncertainty by the Mishel Uncertainty in Illness Scale-Community Form; symptom distress by the Memorial Symptom Assessment Scale Short Form; and comorbidity by the Charlson Comorbidity Index). |
| PROCEDURE | quality-of-life assessment | At 1 month after completion of radiotherapy, patients undergo repeat assessment of stress appraisal and psychosocial adjustment. |
Timeline
- Start date
- 2008-08-01
- Primary completion
- 2009-02-01
- Completion
- 2009-05-01
- First posted
- 2009-05-20
- Last updated
- 2015-09-30
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00905086. Inclusion in this directory is not an endorsement.